What are the precautions for Rytelo (Imetelstat)?

Rytelo (Imetelstat) is an injectable drug for the treatment of low-to-moderate risk myelodysplastic syndrome (MDS). It has a relatively good therapeutic effect in clinical application, but it is also accompanied by a series of special needs. Special precautions include thrombocytopenia, neutropenia, infusion-related reactions, embryo-fetotoxicity, etc. Discontinue the drug and resume at a reduced dose after recovery, or permanently discontinue based on the severity.

1. Thrombocytopenia: Based on laboratory values,Rytelo can cause thrombocytopenia, which may include gastrointestinal bleeding and hematuria. Monitor patients with thrombocytopenia for bleeding. Monitor complete blood counts before starting Rytelo, once weekly for the first two cycles, before each cycle thereafter, and as clinically indicated. Transfuse platelets appropriately.

2. Neutropenia: According to laboratory values,Rytelo can cause neutropenia, which may include febrile neutropenia, sepsis, etc. MonitorPatients with grade 3 or 4 neutropenia for infections, including sepsis. Monitor complete blood counts before starting Rytelo, weekly for the first two cycles, before each cycle thereafter, and as clinically indicated. Use growth factors and anti-infective therapies for treatment or prevention as appropriate.

3. Infusion-related reactions:Rytelo can cause infusion-related reactions. The most common reaction is headache. Infusion-related reactions usually occur during the infusion process or shortly after the end of the infusion. It is recommended to administer diphenhydramine and hydrocortisone to patients at least30 minutes before infusion and to monitor patients for at least one hour after infusion. If symptoms of an infusion-related reaction occur, symptoms can be controlled with supportive care, controlling the rate of infusion, or interrupting the infusion. Disable Rytelo permanently if necessary, or as recommended.

4. Embryo-Fetal Toxicity: According to the results of animal studies, Rytelo can cause embryo-fetal damage when administered to pregnant women. In animal reproduction studies, administration of Rytelo to pregnant mice during organogenesis resulted in embryo-fetal mortality (AUC) at maternal exposure that was 2.5 times greater than human exposure at recommended clinical doses. Inform pregnant women of potential risks to the fetus. Advise females of reproductive potential to use effective contraception during treatment with Rytelo and for 1 week after the last dose.

In short, useWhen treating MDS with Rytelo, precautions such as thrombocytopenia, neutropenia, infusion-related reactions, and embryo-fetal toxicity need to be noted. During use, the patient's condition should be closely monitored and appropriate treatment and preventive measures taken as needed. In the event of serious adverse reactions or side effects, the drug should be discontinued promptly and guidance from a doctor should be sought.